Get Proactive With Your Stability Program

Greg Pirozzi has 30 years of biotechnology industry experience with more than 20 years in various project management and technology development roles. In his current role, Greg manages a broad range of client projects including analytical and molecular assay development, transfer and validations, as well as extensive stability studies covering bulk, final drug product, and cell bank materials.

Previously, Greg led a variety of drug development projects including biologics and viral vectors for oncology, cardiovascular, ocular, and infectious disease vaccines and therapies. Greg holds a Ph.D. from New York University Medical Center.

Pamela Hamill is a subject matter expert for product characterization, providing technical, scientific, and regulatory support for clients and specializing in strategies to understand product critical quality attributes and the functional activity of biologics through the use of binding and bioassays.

Prior to joining the organization, Pamela managed a national Level III diagnostic lab and worked in academic research focused on innate immunity, novel host defense peptides, and the development of assays enabling analysis of viral proteases and antiviral drug screening. She holds a Ph.D. and M.Sc. from the University of Glasgow.